Angiotensin-Receptor Blockers Linked to 'Modest' Increase in Cancer Risk

Angiotensin-receptor blockers (ARBs) are associated with a modestly increased risk for cancer, according to a meta-analysis published in the Lancet Oncology.

Researchers, examining data from five randomized trials comprising nearly 62,000 patients, found that those taking ARBs (85% were using telmisartan) had a significantly greater risk for new cancer than did controls (7.2% vs. 6.0%). When cancer type was analyzed, only lung cancer risk was significantly increased. The authors estimate that 143 patients would need to be treated for roughly 4 years for one excess cancer to occur.

The authors call the increase in cancer risk "modest" and the mechanism "uncertain." In addition, they note that conclusions could not be made regarding the exact risk with individual ARBs.

In an accompanying commentary, Dr. Steven Nissen says that until we have more data, clinicians "should use ARBs, particularly telmisartan, with greater caution." He recommends reserving the drugs for patients who cannot tolerate ACE inhibitors.